Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)

Objective: To investigate adverse events (AEs) associated with denosumab (Dmab) and zoledronic acid (ZA), compare their association strengths, and explore potential applications to provide clinical reference. Methods: We collected data from FAERS from January 2004 to November 2022 and mined AE signa...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Si, Wu, Liuqing, Zhou, Guibao, Peng, Lingling, Zhao, Huanzhe, Wang, Xiao, Li, Kuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654638/
https://www.ncbi.nlm.nih.gov/pubmed/38027014
http://dx.doi.org/10.3389/fphar.2023.1225919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654638/
https://www.ncbi.nlm.nih.gov/pubmed/38027014
http://dx.doi.org/10.3389/fphar.2023.1225919

Ejemplares similares